Propyphenazone
Template:Short description Template:Drugbox
Propyphenazone (known as isopropylantipyrine in Japan)[1] is a derivative of phenazone[2] with similar analgesic and antipyretic effects. Originally patented in 1931,[3] propyphenazone is marketed as a combination formulation with paracetamol and caffeine for treatment of primary headache disorder.[4]
Serious adverse events
Case reports have described acute inferior-wall myocardial infarctions characterized by low atrial rhythmsScript error: No such module "Unsubst". (Kounis syndrome) secondary to propyphenazone use.[5]
Excerpt from WHO comments
Banned
Propyphenazone is banned in some countries including Sri Lanka,[6] Malaysia,[6] and Thailand.[6]
Synthesis
Ethyl 2-isopropylacetoacetate (1) and phenylhydrazine (2) are combined to form the pyrazolone ring in the intermediate (3), which is alkylated with methyl iodide to yield propyphenazone.[7][8]
See also
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ a b c Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".
Script error: No such module "navbox".